Does Testosterone Stop Periods? Timeline and Effects

Testosterone therapy stops menstrual periods for most people who take it, but the timeline varies and the process is rarely instant. In clinical studies, roughly half of transgender men on injectable testosterone reach full cessation within two to six months, while a meaningful minority still experience some bleeding beyond the six-month mark. How quickly periods stop, what factors influence the timeline, and whether amenorrhea truly means the reproductive system has gone quiet are all more complicated than the simple “testosterone stops your period” framing suggests.

How Quickly Periods Typically Stop

The most detailed look at how fast periods disappear comes from a study that tracked 74 transgender men starting intramuscular testosterone injections. About 5% stopped bleeding within the first month. Half achieved cessation somewhere between months two and six. Around a third took longer than six months, and a small group was still menstruating at the one-year mark even on steady doses.¹ Those numbers sketch a range, not a single answer. A person starting testosterone should expect their periods to become lighter and less frequent over the first few months, with full cessation usually arriving within six months of consistent use.

Clinical guidance generally treats bleeding that persists beyond six months of continuous testosterone use as something worth investigating. At that point, checking hormone levels to confirm testosterone is in the target range is standard practice, along with further evaluation if levels look appropriate and bleeding continues.²

Why It Takes Longer for Some People

Testosterone suppresses menstruation by disrupting the hormonal feedback loop that drives the menstrual cycle. Researchers believe it interferes with the signals from the brain to the ovaries, either directly or through conversion of testosterone into estradiol, which then disrupts the normal pulsing of reproductive hormones.³ That suppression does not flip like a switch. It ramps up gradually as testosterone levels stabilize, which is why periods tend to get lighter and more irregular before they disappear entirely.

A large survey of 382 transgender people on testosterone found that about 23% reported persistent menstruation more than six months after starting treatment.⁴ That is not a trivial fraction, and the study turned up some interesting patterns in who was more likely to keep bleeding. The delivery method made a striking difference: people using testosterone gels or creams had far higher odds of persistent menstruation compared to those on injections. The likely explanation is that topical formulations produce lower and more variable testosterone levels, which may not suppress the reproductive axis as consistently. On the other hand, people with a higher body mass index were actually less likely to report persistent bleeding. Neither age at starting treatment nor how regular periods were beforehand predicted the outcome.⁴

The takeaway for someone choosing a testosterone formulation is worth noting: injections appear more reliable at stopping periods than topical gels, at least based on the available evidence. That does not mean gels cannot work, but if cessation of menses is a priority, the data leans in favor of injections.

What to Do If Bleeding Persists

For people who keep bleeding despite being on testosterone at appropriate levels, several add-on strategies exist. Progesterone-based methods are the first-line approach. These include progesterone-only pills, injectable medroxyprogesterone acetate (the shot commonly given every three months), or a hormonal intrauterine device. Any of these can be layered on top of testosterone therapy either to speed up cessation at the start of treatment or to address persistent bleeding later.²

Some clinicians use a hormonal IUD as a “bridge” method during the early months of testosterone therapy, helping to manage periods while testosterone levels are still climbing to a suppressive range. For bleeding that does not respond to progesterone-based options, surgical approaches or aromatase inhibitors (drugs that block testosterone from converting to estrogen) are discussed as additional options, though the evidence base for aromatase inhibitors in this context is still thin.

Amenorrhea Does Not Mean You Cannot Get Pregnant

This is one of the most consequential misconceptions in transgender health care. It is widely assumed that once periods stop on testosterone, ovulation has stopped too. That turns out to be wrong for a significant number of people. A study examining ovarian tissue at the time of gender-affirming oophorectomy (surgical removal of the ovaries) found histological signs of recent ovulation in about a third of amenorrheic transmasculine individuals who had been on adequate testosterone therapy.⁵ The presence of structures like a corpus luteum or corpus albicans indicated that eggs had recently been released, even though these individuals had no menstrual bleeding and their testosterone levels were in the expected range.

The duration of testosterone use, the specific testosterone levels, and the type of testosterone formulation did not correlate with whether someone was still ovulating. In other words, there was no reliable marker that distinguished people who had truly stopped ovulating from those who had not. The researchers were emphatic that testosterone is not a contraceptive, and that anyone engaging in sexual activity that could result in pregnancy needs a separate birth control method.⁶ Testosterone is also considered harmful to a developing fetus, which makes unplanned pregnancy in this context an especially serious concern.

What Happens to the Uterus on Testosterone

A question that often follows “will my periods stop?” is “what is testosterone doing to my uterus in the meantime?” The available evidence is reassuring on this front. Ultrasound studies show that the endometrial lining becomes significantly thinner in transmasculine people on testosterone compared to cisgender women without testosterone exposure.⁷ This suggests that rather than building up a thick lining that never sheds (which would be a concern for cancer risk), testosterone actually suppresses endometrial growth.

Tissue studies confirm this pattern. In one analysis of transgender men who had been on testosterone for an average of about five years, roughly two-thirds had an atrophic (thin and inactive) endometrium.⁸ The remaining third showed a mix of proliferative and secretory patterns, which are normal states the endometrium can be in and are not inherently worrisome. Another multicenter case series found active endometrium in the majority of surgical specimens, with only one case of complex hyperplasia (a benign overgrowth) and no cases of endometrial cancer.⁹

A systematic review synthesizing data from over 500 patients found a low rate of endometrial intraepithelial neoplasia (a precancerous change) at about 2.3%, with only a single case of focal adenocarcinoma. The review concluded that patients on testosterone do not appear to face increased risk of precancerous endometrial changes due to their amenorrhea.¹⁰ This is important because in cisgender women, amenorrhea from conditions like polycystic ovary syndrome can be associated with endometrial buildup and heightened cancer risk. The mechanism with testosterone is different: the lining thins rather than thickens.

Fertility and Ovarian Reserve

Whether testosterone permanently affects the ability to have biological children is one of the most common concerns, and the evidence so far is more encouraging than many people expect. A longitudinal study tracking ovarian reserve markers found that anti-Müllerian hormone (a blood marker of egg supply) and antral follicle count (a count of developing egg-containing structures visible on ultrasound) were largely preserved over 12 months of testosterone therapy in individuals without polycystic ovary syndrome. In those who did have PCOS, there was a notable decline in both markers, but this may reflect a correction from the elevated baseline that PCOS typically causes rather than genuine damage.¹¹

Perhaps most compellingly, in the cross-sectional arm of that study, ovarian reserve markers in people who had been on testosterone for varying lengths of time tracked with age, not with treatment duration. Four men in the cohort had fathered biological children after being on testosterone for up to 12 years.¹¹ A separate literature review examining ovarian tissue found normal proportions of healthy follicles at various developmental stages, and oocyte quality after ovarian stimulation did not appear impaired, with successful pregnancies and healthy births reported.¹²

The ovaries do show structural changes on testosterone. The same review noted a higher number of atretic (degenerating) and cystic follicles, along with thickening of the outer ovarian tissues. These changes resemble what is seen in polycystic ovaries, but they do not appear to translate into meaningful fertility loss, at least based on the outcomes data available so far. That said, most of the fertility research involves people who had been on testosterone for a few years. Whether very long-term use, spanning decades, affects fertility differently is still genuinely unknown.

Pelvic Pain on Testosterone

Some people develop pelvic pain after starting testosterone, and a few patterns have emerged from the research. A study examining pelvic pain specifically in transgender people on testosterone found that persistent menstruation was the strongest predictor of pelvic pain, with people still bleeding having over four times the odds of reporting it.¹³ A history of PTSD was also associated with higher odds of pelvic pain, and there was a strong link between pelvic pain and pain during orgasm.

The causes of pelvic pain in this context are likely multifactorial. Testosterone can cause vaginal and cervical tissue changes that may contribute to discomfort. The partial suppression of the menstrual cycle, where the hormonal signals are disrupted but not fully silenced, may also produce cramping or discomfort in some individuals. For people experiencing persistent pelvic pain, addressing any ongoing bleeding through the methods described earlier is a reasonable first step, along with discussing pain management with a provider familiar with transgender health care.

Bone Health After Years of Treatment

Testosterone itself is generally considered bone-protective, but the story gets more nuanced over time, particularly after surgical removal of the ovaries. A study tracking bone density over five and ten years of testosterone therapy found that Z-scores (a measure of bone density relative to age-matched norms) declined at the spine, total hip, and femoral neck by the five-year mark. When the researchers split the group by whether they had undergone oophorectomy, the significant declines were concentrated in the surgical group. That group also had substantially lower estradiol levels, suggesting that the loss of residual estrogen production from the ovaries plays a role in the bone density decline.¹⁴

This finding is clinically relevant for anyone considering oophorectomy as part of their transition. Testosterone does get partially converted to estradiol in the body, and this converted estrogen helps maintain bone. But after the ovaries are removed, that internal source of estrogen drops considerably, and the testosterone-to-estradiol conversion may not fully compensate. Whether the bone density decline translates into higher fracture risk over a lifetime is not yet established, but the data suggest that monitoring bone health is worthwhile, especially for people who have had their ovaries removed.

The PCOS Connection

People with a prior diagnosis of polycystic ovary syndrome seem to respond to testosterone somewhat differently in a few ways worth knowing about. The ovarian reserve study mentioned earlier found that the decline in anti-Müllerian hormone and follicle counts during the first year of testosterone was driven entirely by the PCOS subgroup. Those without PCOS saw no measurable change, while those with PCOS saw a statistically significant drop in both markers.¹¹ This likely reflects the fact that PCOS elevates these markers above normal to begin with, so testosterone may partially normalize them rather than damage anything.

Interestingly, PCOS status did not predict whether someone’s periods would persist longer than six months on testosterone. The survey data showed that menstrual regularity before starting testosterone had no bearing on how quickly bleeding stopped afterward.⁴ So while PCOS affects some of the ovarian biomarkers, it does not appear to make it harder to achieve amenorrhea. If you had irregular periods before testosterone, that does not mean you will have a harder or easier time stopping them.

What Happens If You Stop Testosterone

For people who discontinue testosterone, menstrual periods generally return, though the timeline is variable and less well-studied than the cessation timeline. The fact that ovarian reserve and follicle counts appear largely preserved during treatment supports the expectation that the reproductive axis can resume cycling once testosterone is withdrawn. Case reports and the fertility data, including those individuals who conceived after years of testosterone use, confirm that the suppressive effects are reversible for most people. However, “reversible” does not mean “immediate.” It can take weeks to months for the hormonal feedback loop to re-establish regular cycling, similar to how periods may take time to return after discontinuing long-acting hormonal contraceptives.

The structural ovarian changes observed on testosterone, such as cortical thickening and increased cystic follicles, have not been studied long enough after discontinuation to know with certainty how quickly they resolve or whether they affect the speed of menstrual return. For anyone planning to stop testosterone with the goal of conceiving, consulting a reproductive endocrinologist familiar with transgender care is a practical step to set realistic expectations and optimize the timeline.

1
PubMed Central. The Response of the Menstrual Cycle to Initiation of Hormonal Therapy in Transgender Men
2
Obstetrics & Gynecology. Approaches to Vaginal Bleeding and Contraceptive Counseling in Transgender and Gender Nonbinary Patients
3
PubMed Central. The effect of testosterone on ovulatory function in transmasculine individuals
4
PubMed Central. Persistent menstruation in transgender people using testosterone gender-affirming hormone therapy
5
Cell Reports Medicine. One-third of amenorrheic transmasculine people on testosterone ovulate
6
Cell Reports Medicine. Recent ovulatory activity in amenorrheic transmasculine people on adequate testosterone therapy
7
PubMed. Endometrial thickness assessed by transvaginal ultrasound in transmasculine people taking testosterone compared with cisgender women
8
European Journal of Endocrinology. Uterine changes in transgender men receiving testosterone therapy
9
American Journal of Obstetrics and Gynecology. Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series
10
PubMed Central. Uterine and Ovarian Histopathology After Testosterone for Gender Affirmation: A Systematic Review
11
Human Reproduction. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment
12
PubMed Central. The effect of gender-affirming testosterone therapy on ovarian function and oocyte quality in transgender men: a literature review
13
PubMed Central. Pelvic Pain in Transgender People Using Testosterone Therapy
14
Frontiers in Endocrinology. Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy